Leerink Partners Reaffirms “Market Perform” Rating for Affimed (NASDAQ:AFMD)

Leerink Partners reaffirmed their market perform rating on shares of Affimed (NASDAQ:AFMD) in a research report report published on Tuesday morning, MarketBeat.com reports. The firm currently has a $0.39 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $5.00.

Separately, StockNews.com started coverage on Affimed in a report on Sunday, May 11th. They issued a “sell” rating for the company. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $7.90.

Affimed Stock Down 34.5%

Shares of AFMD stock opened at $0.09 on Tuesday. Affimed has a twelve month low of $0.07 and a twelve month high of $8.95. The stock has a fifty day simple moving average of $0.75 and a two-hundred day simple moving average of $1.44. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 0.13.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in AFMD. Northern Trust Corp bought a new position in shares of Affimed in the 4th quarter worth $218,000. Intellectus Partners LLC raised its position in shares of Affimed by 34.0% in the 4th quarter. Intellectus Partners LLC now owns 126,414 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 32,053 shares in the last quarter. Finally, Jane Street Group LLC bought a new position in shares of Affimed in the 3rd quarter worth $44,000. 30.82% of the stock is owned by institutional investors.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.